Investment & Collaboration Opportunities

APIE Therapeutics is developing strong, exclusive global IP through Apelinergic system targets

We have a strong and long-term commitment to develop first-in-class therapies for chronic diseases


Investment Opportunity

APIE Therapeutics initiated a $35M Series A financing round to carry the lead compound, APT101, from IND enabling through IND clearance and a planned Phase 1 clinical study for the indication of system sclerosis (SSC) / systemic sclerosis-interstitial lung disease (SSc-ILD).

Phase 1 clinical trials are anticipated to begin in 2024.

Collaboration Opportunities

We are looking for collaborations to develop drug programs in the following diseases:


Covid 19

Capillary Leak Syndrome (Clarkson disease)


Kidney Nephrotic Syndrome